TIDMPRTC
RNS Number : 7406P
PureTech Health PLC
12 June 2020
12 June 2020
PureTech Health plc
Results of Annual General Meeting
The Annual General Meeting of PureTech Health plc (LSE: PRTC)
("PureTech Health" or the "Company"), was held at 16.00 BST on
Thursday 11 June 2020. All of the resolutions proposed at the
Annual General Meeting were duly passed by the shareholders on a
poll.
The results of the poll, incorporating the proxy votes lodged in
advance of the meeting, are set out below. All resolutions were
passed by greater than 94% of the shares voted at the meeting.
Resolutions For % Against % Withheld Total
votes
cast
001. To approve
the Company's
Annual Report
and Accounts for
year ended 31
December 2019 218,866,084 98.3 3,775,464 1.7 125 222,641,548
------------ ------ ----------- ----- --------- ------------
002. To approve
the Directors'
Remuneration Report 214,646,352 96.41 7,995,196 3.59 125 222,641,548
------------ ------ ----------- ----- --------- ------------
003. To approve
the Directors'
Remuneration Policy 217,657,809 97.77 4,957,219 2.23 26,645 222,615,028
------------ ------ ----------- ----- --------- ------------
004. To elect
Dr. Raju Kucherlapati
as a director 222,641,674 100 0 0 0 222,641,674
------------ ------ ----------- ----- --------- ------------
005. To elect
Dr. John LaMattina
as a director 210,751,824 94.66 11,889,849 5.34 0 222,641,673
------------ ------ ----------- ----- --------- ------------
006. To elect
Dame Marjorie
Scardino as a
director 219,594,272 98.63 3,047,401 1.37 0 222,641,673
------------ ------ ----------- ----- --------- ------------
007. To elect
Mr. Christopher
Viehbacher as
a director 217,521,999 97.7 5,119,675 2.3 0 222,641,674
------------ ------ ----------- ----- --------- ------------
008. To elect
Dr. Robert Langer
as a director 213,520,401 95.9 9,121,272 4.1 0 222,641,673
------------ ------ ----------- ----- --------- ------------
009. To elect
Ms. Daphne Zohar
as a director 222,641,674 100 0 0 0 222,641,674
------------ ------ ----------- ----- --------- ------------
010. To elect
Mr. Stephen Muniz
as a director 222,519,798 99.97 64,000 0.03 57,876 222,583,798
------------ ------ ----------- ----- --------- ------------
011. To reappoint
KPMG LLP as Auditors
of the Company 218,703,302 98.23 3,933,469 1.77 4,902 222,636,771
------------ ------ ----------- ----- --------- ------------
012. To authorise
the Audit Committee
to determine the
Auditors' remuneration 221,766,308 99.65 770,463 0.35 104,902 222,536,771
------------ ------ ----------- ----- --------- ------------
013. To authorise
the allotment
of shares 221,949,357 99.69 692,317 0.31 0 222,641,674
------------ ------ ----------- ----- --------- ------------
014. To dis-apply
pre-emption rights 222,634,253 100 7,421 0 0 222,641,674
------------ ------ ----------- ----- --------- ------------
015. To further
dis-apply pre-emption
rights for acquisitions
and specified
capital investments. 222,560,776 99.96 80,897 0.04 0 222,641,673
------------ ------ ----------- ----- --------- ------------
016. To authorise
market purchase
of own shares 218,863,659 98.3 3,778,014 1.7 0 222,641,673
------------ ------ ----------- ----- --------- ------------
017. To authorise
general meetings
to be called on
not less than
14 clear days'
notice 221,761,669 99.6 880,005 0.4 0 222,641,674
------------ ------ ----------- ----- --------- ------------
Due to its shareholding in the Company, Invesco Asset Management
Limited is deemed to be a controlling shareholder as defined in the
Financial Conduct Authority's Listing Rules. Accordingly, each
resolution to elect an independent director (resolutions 4, 5 and
6) has under Listing Rule 9.2.2E been approved by a majority of the
votes cast by:
-- the shareholders of the Company as a whole; and
-- the independent shareholders of the Company, that is, all the
shareholders entitled to vote on each resolution excluding the
controlling shareholder as shown below.
Resolutions For % Against % Withheld Total
votes
cast
004. To elect
Dr. Raju Kucherlapati
as a director 134,293,959 100 0 0 0 134,293,959
------------ ------ ----------- ----- --------- ------------
005. To elect
Dr. John LaMattina
as a director 122,404,109 91.15 11,889,849 8.85 0 134,293,958
------------ ------ ----------- ----- --------- ------------
006. To elect
Dame Marjorie
Scardino as a
director 131,246,557 97.73 3,047,401 2.27 0 134,293,958
------------ ------ ----------- ----- --------- ------------
Notes:
(1) A vote "Withheld" is not a vote in law and is not counted in
the calculation of the votes "For" or "Against" a resolution.
(2) As at 11 June 2020, the number of issued shares in the
Company was 285,488,105 ordinary shares, which was the total number
of shares entitling the holders to attend and vote for or against
all the resolutions at the AGM. In accordance with the Company's
Articles of Association, on a poll every member present in person
or by proxy has one vote for every share held.
(3) The full text of the resolutions may be found in the Notice
of the Annual General Meeting, copies of which are available on
both the Company's website www.puretechhealth.com and on the
National Storage Mechanism.
(4) In accordance with Listing Rule 9.6.2, a copy of the
resolutions, other than those concerning ordinary business has been
submitted to the National Storage Mechanism and will shortly be
available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercialising highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 23 product candidates and one product that has been
cleared by the US Food and Drug Administration (FDA). All of the
underlying programmes and platforms that resulted in this pipeline
of product candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company's unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Stephanie Simon
+1 617 651 3156 +44 (0) 20 3727 1000 +1 617 581 9333
amt@puretechhealth.com ben.atwell@FTIconsulting.com stephanie@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGKKDBQKBKBCAD
(END) Dow Jones Newswires
June 12, 2020 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Aug 2023 to Aug 2024
